var title_f6_28_6592="Statin benefits by tertile HPS";
var content_f6_28_6592=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Benefits of simvastatin therapy in different risk groups in HPS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 517px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Summary of the benefits of allocation to simvastatin therapy in the Heart Protection Study according to different patient characteristics. The relative benefits of simvastatin therapy compared with placebo in terms of reduction in first major vascular events were significant in all patient groups, including patients with LDL cholesterol values below 116 mg/dL (3.0 mmol/L).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_28_6592=[""].join("\n");
var outline_f6_28_6592=null;
var title_f6_28_6593="Ectopia cordis";
var content_f6_28_6593=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Ectopic cordis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The heart is protruding through a defect in the chest wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Courtney D Stephenson, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_28_6593=[""].join("\n");
var outline_f6_28_6593=null;
var title_f6_28_6594="Patient information: Lichen planus (The Basics)";
var content_f6_28_6594=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/87110\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/21/12630\">",
"         Lichen planus",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?42/60/43970\">",
"         Patient information: Dyspareunia (painful sex) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/12/14530\">",
"         Patient information: Lichen sclerosus (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/54/33634\">",
"         Patient information: Vulvar itching (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/33/36370\">",
"         Patient information: Vulvar pain (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/30/27106\">",
"         Patient information: Lichen sclerosus (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Lichen planus (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H12718985\">",
"      <span class=\"h1\">",
"       What is lichen planus?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Lichen planus is a condition that causes red, purple, or white spots to form on the skin. These spots often itch or hurt. Lichen planus can affect the skin anywhere on the body, including the skin in and around the vagina and penis, and the pink, moist skin that lines the mouth.",
"     </p>",
"     <p>",
"      In most cases, doctors do not know what causes lichen planus.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12719000\">",
"      <span class=\"h1\">",
"       What are the symptoms of lichen planus?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Lichen planus causes different symptoms, depending on which part of the body is affected.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        On the",
"        <strong>",
"         skin",
"        </strong>",
"        , it usually causes shiny, flat, red, or purple spots (",
"        <a class=\"graphic graphic_picture graphicRef87024 \" href=\"UTD.htm?12/21/12630\">",
"         picture 1",
"        </a>",
"        ). These spots tend to form on the wrists, arms, or legs, but might also show up on other areas. The spots are often very itchy. As the spots heal, they can turn dark.",
"       </li>",
"       <li>",
"        On the",
"        <strong>",
"         nails",
"        </strong>",
"        , it can cause lines or ridges to form.",
"       </li>",
"       <li>",
"        On the",
"        <strong>",
"        </strong>",
"        &ldquo;",
"        <strong>",
"         mucous membranes",
"        </strong>",
"        ,&rdquo; the pink moist skin that lines the inside of the mouth, the vagina, and other organs, it can cause redness, painful sores, or patterns that look like white lace. When lichen planus affects the mouth, it can make it hard to eat.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12719041\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, if you have symptoms like those listed above, see your doctor or nurse.",
"     </p>",
"     <p>",
"      Your doctor or nurse will probably be able to tell if you have lichen planus by learning about your symptoms and doing an exam. It&rsquo;s also possible your doctor or nurse will take a small sample of skin to send to the lab. This is called a skin &ldquo;biopsy.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12719058\">",
"      <span class=\"h1\">",
"       How is lichen planus treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment is different depending on which part of the body is affected and how bad the symptoms are. In general, treatment can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Steroid medicines that come in ointments, creams, or gels &ndash; These steroid medicines reduce inflammation and help the skin heal. Examples include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?8/16/8452?source=see_link\">",
"         fluocinonide",
"        </a>",
"        or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?13/34/13860?source=see_link\">",
"         clobetasol",
"        </a>",
"        .",
"       </li>",
"       <li>",
"        Medicines called calcineurin inhibitors, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?3/7/3189?source=see_link\">",
"         pimecrolimus",
"        </a>",
"        (brand name: Elidel) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?37/24/38272?source=see_link\">",
"         tacrolimus",
"        </a>",
"        (brand name: Protopic)",
"       </li>",
"       <li>",
"        Medicines that numb the skin and help with pain, especially for people who have sores on their mouth or sex organs",
"       </li>",
"       <li>",
"        Pills that help to reduce inflammation and help the skin heal",
"       </li>",
"       <li>",
"        A special type of light treatment called phototherapy",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people need to try more than 1 medicine before they find the medicine that works best for them.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12719073\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Here are some things you should do:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Take good care of your skin. Wash and dry your skin gently when you take a shower or bath. Try not to scratch itchy skin because that can increase the chance of infection. Scratching can also make lichen planus worse.",
"       </li>",
"       <li>",
"        If you have lichen planus in your mouth, make sure you take good care of your teeth and gums. You should brush your teeth twice a day with a soft brush and floss every day. Not taking good care of your mouth could make lichen planus worse and might cause other problems from unhealthy teeth and gums.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12719088\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/12/14530?source=see_link\">",
"       Patient information: Lichen sclerosus (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/54/33634?source=see_link\">",
"       Patient information: Vulvar itching (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/33/36370?source=see_link\">",
"       Patient information: Vulvar pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/60/43970?source=see_link\">",
"       Patient information: Dyspareunia (painful sex) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/30/27106?source=see_link\">",
"       Patient information: Lichen sclerosus (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?6/28/6594?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87110 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-5115C1355F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_28_6594=[""].join("\n");
var outline_f6_28_6594=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12718985\">",
"      What is lichen planus?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12719000\">",
"      What are the symptoms of lichen planus?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12719041\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12719058\">",
"      How is lichen planus treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12719073\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12719088\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/87110\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/21/12630\">",
"      Lichen planus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/60/43970?source=related_link\">",
"      Patient information: Dyspareunia (painful sex) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/30/27106?source=related_link\">",
"      Patient information: Lichen sclerosus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/12/14530?source=related_link\">",
"      Patient information: Lichen sclerosus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/54/33634?source=related_link\">",
"      Patient information: Vulvar itching (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/33/36370?source=related_link\">",
"      Patient information: Vulvar pain (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_28_6595="Chondrosarcoma Light";
var content_f6_28_6595=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chondrosarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a moderately well differentiated chondrosarcoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Silloo B Kapadia, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_28_6595=[""].join("\n");
var outline_f6_28_6595=null;
var title_f6_28_6596="Dutasteride: Patient drug information";
var content_f6_28_6596=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dutasteride: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     see \"Dutasteride: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F163870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Avodart&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Avodart&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692109",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat the signs of an enlarged prostate. It may take a few months to see the full effect.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691387",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help hair growth in male pattern baldness. It may take 3 months to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700974",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give to a child. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dutasteride or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a woman.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If taking for an enlarged prostate, have a rectal exam (to check prostate gland) and blood work (PSA test). Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696747",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not donate blood while using this drug and for 6 months after stopping.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696915",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch capsules if you are pregnant or of childbearing age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697016",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy during care and for 6 months after care ends. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3473515",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast growing prostate cancer may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A lump in the breast or breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12405 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-641A5F4110-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_28_6596=[""].join("\n");
var outline_f6_28_6596=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163870\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854889\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025262\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025261\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025266\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025267\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025269\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025264\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025265\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025270\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025271\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=related_link\">",
"      Dutasteride: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_28_6597="Intrauterine HSV";
var content_f6_28_6597=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Intrauterine herpes simplex virus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hypopigmented, scaling, and crusted erosions of the trunk and extremities in a neonate with intrauterine herpes simplex virus infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Marquez L, Levy ML, Munoz FM, Palazzi DL. A report of three cases and review of intrauterine herpes simplex virus infection. Pediatr Infect Dis J 2011; 30:153. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_28_6597=[""].join("\n");
var outline_f6_28_6597=null;
var title_f6_28_6598="SPTCL";
var content_f6_28_6598=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F82054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F82054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Subcutaneous panniculitis-like T-cell lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 190px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Lobular and septal pattern of subcutaneous infiltration.",
"    <br/>",
"    (B) TIA-1 immunohistochemistry showing characteristic rimming about individual adipocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Elder DE, Elenitsas R, Johnson BL Jr, et al. Lever's Histopathology of the Skin, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_28_6598=[""].join("\n");
var outline_f6_28_6598=null;
var title_f6_28_6599="Coronal CT met well-differentiated NET with mesenteric mass";
var content_f6_28_6599=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Coronal CT of metastatic well-differentiated neuroendocrine tumor with a mesenteric mass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    &nbsp;Metastatic neuroendocrine tumor with mesenteric mass indicating a presumptive small bowel primary. Coronal reformat from a CT scan in equilibrium phase showing a lobulated enhancing mass in the mesentery with a small coarse calcification (thin arrow) and a subcapsular hepatic lesion in segment VII (arrowheads) that is well circumscribed and hypoenhancing at this phase. There is a clip from a prior cholecystectomy (thick arrow) and oral contrast opacification of juejunal and some ileal loops.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martin Smith, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_28_6599=[""].join("\n");
var outline_f6_28_6599=null;
var title_f6_28_6600="Circinate balanitis in reactive arthritis";
var content_f6_28_6600=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57388%7EDERM%2F73795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57388%7EDERM%2F73795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Circinate balanitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shallow erythematous erosions in a circinate distribution are present on the glans.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Callen, MD, FACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Circinate balanitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple moist papules are present on the glans penis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Keat A. Reactive Arthritis. In: Fitzpatrick's dermatology in general medicine, 7th ed, Wolff K, Goldsmith LA, Katz SI, et al (Eds), McGraw-Hill Professional 2003. Copyright &copy; 2003 The McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_28_6600=[""].join("\n");
var outline_f6_28_6600=null;
var title_f6_28_6601="Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm";
var content_f6_28_6601=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/28/6601/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/28/6601/contributors\">",
"     Gregory YH Lip, MD, FRCPE, FESC, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/28/6601/contributors\">",
"     Jordan M Prutkin, MD, MHS, FHRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/28/6601/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/28/6601/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/28/6601/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/28/6601/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/28/6601/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation (AF) can lead to a fall in cardiac output that is often clinically significant. Potential consequences include a fall in blood pressure, decreased exercise capacity, and pulmonary congestion, all of which are manifestations of heart failure (HF) (",
"    <a class=\"graphic graphic_table graphicRef85688 \" href=\"UTD.htm?14/4/14411\">",
"     table 1",
"    </a>",
"    ). In addition, AF and HF often occur together, and each may predispose to the other [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hemodynamic effects of AF and of cardioversion will be reviewed here. The clinical aspects and treatment of AF in patients with HF and cardiomyopathy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link\">",
"     \"Atrial fibrillation in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ADVERSE HEMODYNAMICS IN AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with AF develop a modest decline in left ventricular performance that typically returns to the previous baseline following reversion to sinus rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. The magnitude of this effect and its reversibility were illustrated in a report of 15 patients with AF who were successfully cardioverted and maintained sinus rhythm for one month; 11 of these patients maintained sinus rhythm for three months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/4\">",
"     4",
"    </a>",
"    ]. The mean duration of AF was three months (range 5 to 254 days). The following findings were noted after cardioversion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean left ventricular ejection fraction (LVEF) increased from 47 percent at baseline to 55 percent immediately after cardioversion to 61 percent at one month; there was no further increase at three months. The improvement in LVEF occurred in all but one patient. The maximum improvement in LVEF by one month coincides with the time to full recovery of left atrial contractile function [",
"      <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Atrial stunning'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The increase in LVEF was primarily due to enhanced diastolic filling resulting from two factors: (1) an increase in cycle length, which may involve both regularization of the heart rate and avoidance of short cycle lengths that impair ventricular contractility; and (2) the return of left atrial contractile function, as determined by peak A wave velocity, which increases the atrial contribution to ventricular filling [",
"      <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The improvement in LVEF following reversion to sinus rhythm is associated with an increase in exercise capacity (",
"    <a class=\"graphic graphic_table graphicRef85688 \" href=\"UTD.htm?14/4/14411\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Improved exercise capacity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The deleterious hemodynamic effects of chronic uncontrolled AF are more pronounced in some patients who develop a reversible tachycardia-mediated cardiomyopathy. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Tachycardia-mediated cardiomyopathy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hemodynamic deterioration also occurs in patients with underlying heart failure. This issue was examined in a prospective observational study of 344 patients with heart failure who were initially in sinus rhythm; 28 developed AF over 19 months, 18 of whom developed chronic AF [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/7\">",
"     7",
"    </a>",
"    ]. Chronic AF was associated with significant worsening of New York Heart Associated functional class (mean 2.4 to 2.9) (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ) and a significant reduction in cardiac index (mean 2.2 to 1.8). The relatively modest changes may have reflected excellent control of the ventricular rate (78",
"    <span class=\"nowrap\">",
"     beats/min)",
"    </span>",
"    at the time the measurements were made. Consistent with this hypothesis is the observation that the onset of AF in 8 of the 18 patients with chronic AF was associated with overt cardiac decompensation, which presumably led to therapy to control the ventricular rate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link\">",
"     \"Atrial fibrillation in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Contributing factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following factors may contribute to the adverse hemodynamic changes in AF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A rapid or slow heart rate; if maintained, a chronic tachycardia can lead to a rate-related cardiomyopathy (atrial or ventricular)",
"     </li>",
"     <li>",
"      The irregular rhythm",
"     </li>",
"     <li>",
"      Loss of atrial systole (also called the atrial \"kick\") required for optimal ventricular filling",
"     </li>",
"     <li>",
"      Activation of neurohumoral vasoconstrictors such as angiotensin II and norepinephrine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another problem demonstrated in animal models is that AF may beget AF by causing electrical remodeling of the atria, which promotes perpetuation of the arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. This proarrhythmic process is reversible with the maintenance of sinus rhythm. The clinical relevance of this observation remains uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12266?source=see_link&amp;anchor=H186294983#H186294983\">",
"     \"Mechanisms of atrial fibrillation\", section on 'Maintenance of AF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Rapid ventricular response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dependence of cardiac output on heart rate is greatest in patients with left ventricular dysfunction, which is often associated with a relatively fixed stroke volume. As an example, the cardiac output is optimal over a narrow range of heart rates in patients with a myocardial infarction, falling significantly with slower or faster heart rates [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/10\">",
"     10",
"    </a>",
"    ]. A rapid ventricular response is also particularly deleterious in patients with mitral stenosis in whom the reduction in the duration of diastole diminishes the time available for filling of the left ventricle across the stenotic valve [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal heart rate for patients in permanent AF is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link&amp;anchor=H4#H4\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\", section on 'Rate control goals'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h4\">",
"     Tachycardia-mediated cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent, uncontrolled tachycardia can have a cardiomyopathic effect that impairs left ventricular function. This phenomenon is called a tachycardia-mediated cardiomyopathy and is reversible when the tachycardia is controlled. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link\">",
"     \"Tachycardia-mediated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Atrial fibrillation occurs in 10 to 30 percent of patients with HF. In most of these patients, the underlying heart disease is thought to predispose to AF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link\">",
"     \"Atrial fibrillation in patients with heart failure\"",
"    </a>",
"    .) However, in some patients, restoration of sinus rhythm or control of the rapid ventricular response markedly improves or even normalizes the left ventricular ejection fraction (LVEF), indicating that the left ventricular dysfunction was primarily due to the rapid AF rather than an underlying dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. The benefit may be more predictable with reversion to sinus rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/13,15\">",
"     13,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations illustrate the potential magnitude of this effect:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, the LVEF was measured before and at a mean of 4.7 months after cardioversion in 12 patients with chronic AF and presumed idiopathic dilated cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/13\">",
"       13",
"      </a>",
"      ]. There was an improvement in mean LVEF from 32 percent at baseline to 53 percent at follow-up; the LVEF returned to normal in six of the patients. This improvement persisted at one year in the 10 patients who remained in sinus rhythm, while there was a marked deterioration in left ventricular function in the two patients with recurrent AF.",
"     </li>",
"     <li>",
"      Among patients treated with rate control, the largest reported experience comes from the multicenter Ablate and Pace Trial (APT), a prospective registry of patients undergoing atrioventricular (AV) nodal ablation and pacemaker implantation for refractory AF [",
"      <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/14\">",
"       14",
"      </a>",
"      ]. The registry included 63 patients with left ventricular dysfunction (LVEF &le;45 percent); after AV nodal ablation, 16 (25 percent) displayed a marked improvement in LVEF to over 45 percent. The mean increase in LVEF in these patients was 27 percentage points.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Irregular heart rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypothesis that an irregular rhythm itself, independent of the ventricular rate and the restoration of atrial systole, can impair hemodynamics is based in part upon short-term observations that irregular ventricular pacing or induced AF results in a decrease in cardiac output, an elevation in central venous pressure, and an increase in sympathetic nerve activity compared to regular ventricular or atrial pacing at the same mean heart rate [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further support for the adverse effect of an irregular heart rate comes from a study of 14 patients with chronic AF and a normal ventricular response in the absence of drugs that block AV nodal conduction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/18\">",
"     18",
"    </a>",
"    ]. AV nodal ablation and insertion of a ventricular pacemaker resulted in a regular rhythm, improvements in left ventricular function, functional capacity, and the sense of well-being [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The adverse hemodynamic effect of an irregular rhythm may be mediated by several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beat-to-beat variations in atrial pressure (preload). The influence of preload on left ventricular ejection (Frank-Starling mechanism) is important in AF only when afterload is relatively low [",
"      <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Beat-to-beat variations in myocardial contractility [",
"      <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/20-22\">",
"       20-22",
"      </a>",
"      ]. Among patients with AF, the preceding RR interval has a significant positive correlation with left ventricular ejection, as a shorter RR interval (more rapid ventricular response) reduces the LVEF [",
"      <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/20\">",
"       20",
"      </a>",
"      ]. This effect is independent of end-diastolic volume, indicating that it cannot be explained by the Frank-Starling mechanism. In addition, the \"pre-preceding\" RR interval has a",
"      <strong>",
"       negative",
"      </strong>",
"      correlation with left ventricular ejection, which has been ascribed to postextrasystolic potentiation [",
"      <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/20,23\">",
"       20,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inefficient ventricular mechanics due to abrupt changes in cycle length [",
"      <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Atrial systole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraction of the left atrium injects a volume of blood under pressure into the left ventricle, leading to increments in ventricular diastolic volume, end-diastolic pressure, and stroke volume [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Loss of atrial systole can therefore diminish the stroke volume. This may be particularly important when left ventricular compliance is reduced and in mitral stenosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left ventricular compliance is reduced in patients with diastolic dysfunction. In such patients, there is a relative shift of left ventricular filling to the later part of diastole with a greater dependence upon atrial contraction. Clinical examples in which AF can lead to hemodynamic deterioration in patients with diastolic dysfunction include advanced aortic stenosis, which often produces a hypertrophied, poorly compliant left ventricle, and hypertrophic cardiomyopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of atrial systole has been demonstrated in patients with hypertrophic cardiomyopathy, which is typically associated with an increased atrial contribution to ventricular filling (31 versus 16 percent in controls in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition, loss of the atrial contraction-induced increase in left ventricular end-diastolic volume can increase the degree of outflow tract obstruction. The net effect is that the acute onset of AF leads to worsening symptoms in the great majority of patients with hypertrophic cardiomyopathy (41 of 46 in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\", section on 'Pathophysiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=see_link\">",
"     \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with mitral stenosis, the onset of AF can lead to hemodynamic deterioration. Two factors contribute to this adverse effect: the loss in atrial systole, which plays an important role in the generation of adequate left atrial pressure to maintain blood flow across the stenotic valve and may also reduce effective mitral valve area; and the rapid ventricular response which, due to the reduction in the duration of diastole, diminishes the time available for filling of the left ventricle [",
"      <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relevance of atrial systole, irregular rate, and ejection fraction was assessed in patients with systolic heart failure who underwent atrial fibrillation ablation versus AV node ablation with biventricular pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/28\">",
"     28",
"    </a>",
"    ]. In those who underwent atrial fibrillation ablation, there was a greater improvement in ejection fraction, six-minute walk test, and quality of life scores. It is not clear, however, whether it was due to the restoration of sinus rhythm in the atrial fibrillation group or presence of pacing, even though it was biventricular, in the AV node ablation group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Neurohumoral activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fall in cardiac output in rapid AF may increase afterload by activating neurohumoral vasoconstrictors. In addition, AF may reversibly increase the secretion of atrial natriuretic peptide [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/29,30\">",
"     29,30",
"    </a>",
"    ] which, via activation of other propeptides and neurohumoral mechanisms, could influence systemic hemodynamics. As an example, one study of 100 patients with and without AF found that patients with AF had higher levels of N-terminal ANP (2.6 versus 1.7",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in those without AF); this association was independent of left atrial volume and left ventricular ejection fraction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/31\">",
"     31",
"    </a>",
"    ]. In patients with HF and AF, the association between AF and ANP interferes with the association between left ventricular dysfunction and ANP.",
"   </p>",
"   <p>",
"    While one study did not find a higher level of plasma B-type natriuretic peptide (BNP) in AF patients compared to those without [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/31\">",
"     31",
"    </a>",
"    ], other studies have [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .) The relationship between baseline BNP and recurrence of AF after successful AF ablation is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link&amp;anchor=H22#H22\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\", section on 'AF recurrence after three months'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6881060\">",
"    <span class=\"h3\">",
"     Mitral regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary data has suggested that, in a small number of patients, atrial fibrillation can lead to increased mitral annular dilatation and mitral regurgitation (MR). This was shown in a report of 12 patients (out of 18,695 open heart surgeries) who had atrial fibrillation and moderate or greater MR, with normal left ventricular size and function but symptoms of dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/34\">",
"     34",
"    </a>",
"    ]. They underwent mitral ring annuloplasty and surgical ablation, with an improvement in symptoms and MR. The presence of atrial fibrillation can create a cycle of worsening atrial fibrillation burden and increasing mitral regurgitation, which can be reversed with a persistent return to normal sinus rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/35\">",
"     35",
"    </a>",
"    ]. Increased left atrial size in the presence of normal left ventricular function has been associated with increased mitral annular size and more severe mitral regurgitation in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/36\">",
"     36",
"    </a>",
"    ], but not in all [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HEMODYNAMICS AFTER CONVERSION OF CHRONIC AF TO SINUS RHYTHM",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the restoration of sinus rhythm produces a rapid increase in LVEF in most patients with AF [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In one report, for example, the LVEF increased from 47 to 55 percent immediately after cardioversion and to 61 percent at one month [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/4\">",
"     4",
"    </a>",
"    ]. The improvement in LVEF was primarily due to enhanced diastolic filling resulting from two factors: an increase in cycle length, which may involve both regularization of the heart rate and avoidance of short cycle lengths that impair ventricular contractility; and the return of left atrial contractile function. There appears to be no change in markers of intrinsic myocardial contractility.",
"   </p>",
"   <p>",
"    A similar improvement in LVEF has been demonstrated in patients treated with radiofrequency catheter ablation to maintain sinus rhythm. The magnitude of this effect was illustrated in a report of 58 patients with heart failure and AF in whom the mean LVEF improved from 35 to 56 percent and the mean NYHA class fell from 2.3 to 1.4 (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ) after successful ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/39\">",
"     39",
"    </a>",
"    ]. The greatest improvement was seen within the first three months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link&amp;anchor=H8#H8\">",
"     \"Atrial fibrillation in patients with heart failure\", section on 'Rhythm control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Atrial stunning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardioversion of AF leads to an increased risk of thromboembolism, particularly if patients are not anticoagulated before, during, and after the procedure. Most emboli occur within the first week after cardioversion. In addition to dislodgement of preexisting thrombi, some patients develop de novo thrombi that are thought to be due at least in part to persistent depression of left atrial systolic function, which can last for several weeks after successful cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link&amp;anchor=H2#H2\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\", section on 'Left atrial thrombus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The transient atrial contractile dysfunction following cardioversion, also known as atrial \"stunning,\" may result from a tachycardia-induced atrial cardiomyopathy, which is caused in part by impaired cellular handling of calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. An evaluation of stunning in a canine model revealed the following [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stunning occurred with AF duration of only one hour. In this study and in reports of humans with AF and atrial flutter [",
"      <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/42,44\">",
"       42,44",
"      </a>",
"      ], the peak left atrial contractile velocities were lower after reversion to sinus rhythm than during the arrhythmia.",
"     </li>",
"     <li>",
"      Stunning was more profound and of longer duration in the left atrial appendage than the left atrium itself.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reduced left atrial appendage function occurs with all forms of reversion to sinus rhythm including spontaneous cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/45\">",
"     45",
"    </a>",
"    ], external or internal DC (electric) cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/6,44,46-49\">",
"     6,44,46-49",
"    </a>",
"    ], and pharmacologic cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/50\">",
"     50",
"    </a>",
"    ]. The degree of stunning appears to be greater after electrical compared to spontaneous or pharmacologic cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/45\">",
"     45",
"    </a>",
"    ], but is not related to the total amount of energy used if electrical cardioversion is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estimates of the frequency of early atrial stunning (immediately to within 3 days post-cardioversion) range from 20 to 55 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. At one week, the rate is 10 to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net effect of stunning is that left atrial contractility is reduced by up to 75 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/41\">",
"     41",
"    </a>",
"    ] and left appendage flow velocity falls after the restoration of sinus rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/42,44\">",
"     42,44",
"    </a>",
"    ], which can lead to local stasis, as manifested by the onset of or an increase in spontaneous echo contrast [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/44,48,49\">",
"     44,48,49",
"    </a>",
"    ], and the formation of new thrombi [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/48,51-53\">",
"     48,51-53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link&amp;anchor=H2#H2\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\", section on 'Left atrial thrombus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The duration of the left atrial dysfunction is related in part to the duration of AF [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/6,50\">",
"     6,50",
"    </a>",
"    ]. In a review of 60 patients who underwent successful cardioversion, full recovery of atrial mechanical function was attained within 24 hours in patients with AF for &le;2 weeks, within one week in patients with AF for two to six weeks, and within one month with more prolonged AF [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/6\">",
"     6",
"    </a>",
"    ]. Recovery of atrial function is typically demonstrated by return of peak A wave velocity on Doppler echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/6,50\">",
"     6,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The time course of recovery of left atrial function could explain why the great majority of embolic events in patients who remain in sinus rhythm occur within the first 10 days after cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    De novo thrombus formation can also result in part from activation of the coagulation system and a hypercoagulable state following cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. In one study, for example, an increase in plasma concentrations of the markers of thrombin generation and activity (thrombin-antithrombin complex and fibrinopeptide A) was found soon after pharmacologic cardioversion to sinus rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/56\">",
"     56",
"    </a>",
"    ]. As with atrial function, hemostatic markers return to normal by two to four weeks after cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;An uncommon hemodynamic complication of DC cardioversion is pulmonary edema. In a review of the literature, pulmonary edema was reported in approximately 1.2 percent of cases, half of them within three hours but as late as four days after cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/59\">",
"     59",
"    </a>",
"    ]. A lower incidence of 0.4 percent was noted in a report of consecutive outpatient cardioversions at a single institution [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/60\">",
"     60",
"    </a>",
"    ]. Pulmonary edema after cardioversion is more common in patients with left ventricular dysfunction or valvular heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Possible mechanisms for the development of pulmonary edema after cardioversion include acute left ventricular contractile dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/61\">",
"     61",
"    </a>",
"    ], which may be due in part to transient interruption of myocardial cellular respiration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/62\">",
"     62",
"    </a>",
"    ], acute left atrial dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/46\">",
"     46",
"    </a>",
"    ], and the return of right atrial before left atrial systolic function [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Improved exercise capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, most patients in whom AF is reverted to sinus rhythm have a significant increase in left ventricular ejection fraction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. One beneficial effect of the improvement in hemodynamics is enhanced exercise capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/64-66\">",
"     64-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of this effect was illustrated in a study of 63 consecutive patients with chronic AF who were electrically cardioverted in whom peak oxygen consumption (peak VO2) was measured before and one month after cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/65\">",
"     65",
"    </a>",
"    ]. At one month, the mean peak VO2 in the 37 patients in sinus rhythm had significantly increased from 21.4 to 23.7",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per kg, while those who had reverted to AF showed no change in oxygen consumption. The patients who remained in sinus rhythm also had a significant reduction in peak heart rate and an improvement in New York Heart Association functional class. The benefits from restoration of sinus rhythm were seen in patients with and without underlying heart disease and showed some further improvement at two-year follow-up.",
"   </p>",
"   <p>",
"    Similar benefits were noted in the radiofrequency ablation study of 58 patients with heart failure cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/39\">",
"     39",
"    </a>",
"    ]. The mean NYHA class significantly improved from 2.3 to 1.4 after ablation in association with improvements in quality of life, exercise capacity, and exercise time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link&amp;anchor=H8#H8\">",
"     \"Atrial fibrillation in patients with heart failure\", section on 'Rhythm control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6881162\">",
"    <span class=\"h3\">",
"     Mitral regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study of 53 patients examined the effect of atrial fibrillation ablation in those with at least moderate mitral regurgitation (MR) and ejection fraction &ge;50 percent compared to those with only mild or less MR [",
"    <a class=\"abstract\" href=\"UTD.htm?6/28/6601/abstract/35\">",
"     35",
"    </a>",
"    ]. At baseline, those with at least moderate MR were more likely to have persistent atrial fibrillation, older age, and larger mitral annular dimension. Of those who had a successful atrial fibrillation ablation with no recurrence during follow-up, 76 percent had a reduction in mitral regurgitation to mild or less, whereas only 18 percent in the group with an atrial fibrillation recurrence had an improvement in MR. In addition, those with an apparently successful ablation were found to have a decrease in left atrial volume, mitral annular dimension, and mitral annular jet area, with no change in ejection fraction or left ventricular end diastolic dimension, though there was a small decrease in left ventricular end systolic dimension. The authors use the term &ldquo;atrial functional mitral regurgitation&rdquo; to describe an enlarged left atrium leading to MR in the absence of pathology of the mitral valve, which can improve by atrial fibrillation ablation that decreases left atrial size. The exact relationship to symptoms or mortality associated with this is unknown at the current time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267711034\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many patients with atrial fibrillation (AF) develop a modest decline in left ventricular performance that typically returns to the previous baseline following reversion to sinus rhythm (",
"      <a class=\"graphic graphic_table graphicRef85688 \" href=\"UTD.htm?14/4/14411\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The following factors may contribute to the adverse hemodynamic changes in AF:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A rapid or slow heart rate; if maintained, a chronic tachycardia can lead to a rate-related cardiomyopathy (atrial or ventricular).",
"     </li>",
"     <li>",
"      The irregular rhythm.",
"     </li>",
"     <li>",
"      Loss of atrial systole required for optimal ventricular filling.",
"     </li>",
"     <li>",
"      Activation of neurohumoral vasoconstrictors.",
"     </li>",
"     <li>",
"      Increased mitral regurgitation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The restoration of sinus rhythm produces a rapid increase in left ventricular systolic performance in most patients with AF. This translates into an improvement in exercise capacity.",
"     </li>",
"     <li>",
"      A transient atrial contractile dysfunction may follow cardioversion; it is also known as atrial \"stunning&rdquo;. Atrial stunning may result from a tachycardia-induced atrial cardiomyopathy, which is caused in part by impaired cellular handling of calcium.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/1\">",
"      Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003; 107:2920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/2\">",
"      Rodman T, Pastor BH, Figueroa W. Effect on cardiac output of conversion from atrial fibrillation to normal sinus mechanism. Am J Med 1966; 41:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/3\">",
"      Raymond RJ, Lee AJ, Messineo FC, et al. Cardiac performance early after cardioversion from atrial fibrillation. Am Heart J 1998; 136:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/4\">",
"      Viswanathan K, Daniak SM, Salomone K, et al. Effect of cardioversion of atrial fibrillation on improvement in left ventricular performance. Am J Cardiol 2001; 88:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/5\">",
"      Van Gelder IC, Crijns HJ, Blanksma PK, et al. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol 1993; 72:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/6\">",
"      Manning WJ, Silverman DI, Katz SE, et al. Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol 1994; 23:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/7\">",
"      Pozzoli M, Cioffi G, Traversi E, et al. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998; 32:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/8\">",
"      Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/9\">",
"      Wijffels MC, Kirchhof CJ, Dorland R, et al. Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. Circulation 1997; 96:3710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/10\">",
"      Shillingford J, Thomas M. Hemodynamic effects of acute myocardial infarction in man. Prog Cardiovasc Dis 1967; 9:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/11\">",
"      Nicod P, Hillis LD, Winniford MD, Firth BG. Importance of the \"atrial kick\" in determining the effective mitral valve orifice area in mitral stenosis. Am J Cardiol 1986; 57:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/12\">",
"      Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 69:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/13\">",
"      Kieny JR, Sacrez A, Facello A, et al. Increase in radionuclide left ventricular ejection fraction after cardioversion of chronic atrial fibrillation in idiopathic dilated cardiomyopathy. Eur Heart J 1992; 13:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/14\">",
"      Redfield MM, Kay GN, Jenkins LS, et al. Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clin Proc 2000; 75:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/15\">",
"      Stulak JM, Dearani JA, Daly RC, et al. Left ventricular dysfunction in atrial fibrillation: restoration of sinus rhythm by the Cox-maze procedure significantly improves systolic function and functional status. Ann Thorac Surg 2006; 82:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/16\">",
"      Daoud EG, Weiss R, Bahu M, et al. Effect of an irregular ventricular rhythm on cardiac output. Am J Cardiol 1996; 78:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/17\">",
"      Wasmund SL, Li JM, Page RL, et al. Effect of atrial fibrillation and an irregular ventricular response on sympathetic nerve activity in human subjects. Circulation 2003; 107:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/18\">",
"      Natale A, Zimerman L, Tomassoni G, et al. Impact on ventricular function and quality of life of transcatheter ablation of the atrioventricular junction in chronic atrial fibrillation with a normal ventricular response. Am J Cardiol 1996; 78:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/19\">",
"      Muntinga HJ, Gosselink AT, Blanksma PK, et al. Left ventricular beat to beat performance in atrial fibrillation: dependence on contractility, preload, and afterload. Heart 1999; 82:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/20\">",
"      Gosselink AT, Blanksma PK, Crijns HJ, et al. Left ventricular beat-to-beat performance in atrial fibrillation: contribution of Frank-Starling mechanism after short rather than long RR intervals. J Am Coll Cardiol 1995; 26:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/21\">",
"      Brookes CI, White PA, Staples M, et al. Myocardial contractility is not constant during spontaneous atrial fibrillation in patients. Circulation 1998; 98:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/22\">",
"      Schneider F, Martin DT, Schick EC, Gaasch WH. Interval-dependent changes in left ventricular contractile state in lone atrial fibrillation and in atrial fibrillation associated with coronary artery disease. Am J Cardiol 1997; 80:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/23\">",
"      Hardman SM, Noble MI, Seed WA. Postextrasystolic potentiation and its contribution to the beat-to-beat variation of the pulse during atrial fibrillation. Circulation 1992; 86:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/24\">",
"      Rahimtoola SH, Ehsani A, Sinno MZ, et al. Left atrial transport function in myocardial infarction. Importance of its booster pump function. Am J Med 1975; 59:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/25\">",
"      Linderer T, Chatterjee K, Parmley WW, et al. Influence of atrial systole on the Frank-Starling relation and the end-diastolic pressure-diameter relation of the left ventricle. Circulation 1983; 67:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/26\">",
"      Bonow RO, Frederick TM, Bacharach SL, et al. Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. Am J Cardiol 1983; 51:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/27\">",
"      Robinson K, Frenneaux MP, Stockins B, et al. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol 1990; 15:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/28\">",
"      Khan MN, Ja&iuml;s P, Cummings J, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008; 359:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/29\">",
"      Roy D, Paillard F, Cassidy D, et al. Atrial natriuretic factor during atrial fibrillation and supraventricular tachycardia. J Am Coll Cardiol 1987; 9:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/30\">",
"      Hornestam B, Hall C, Held P, et al. N-terminal proANF in acute atrial fibrillation: a biochemical marker of atrial pressures but not a predictor for conversion to sinus rhythm. Digitalis in Acute Atrial Fibrillation (DAAF) Trial group. Am Heart J 1998; 135:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/31\">",
"      Rossi A, Enriquez-Sarano M, Burnett JC Jr, et al. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol 2000; 35:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/32\">",
"      Jourdain P, Bellorini M, Funck F, et al. Short-term effects of sinus rhythm restoration in patients with lone atrial fibrillation: a hormonal study. Eur J Heart Fail 2002; 4:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/33\">",
"      Silvet H, Young-Xu Y, Walleigh D, Ravid S. Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol 2003; 92:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/34\">",
"      Kihara T, Gillinov AM, Takasaki K, et al. Mitral regurgitation associated with mitral annular dilation in patients with lone atrial fibrillation: an echocardiographic study. Echocardiography 2009; 26:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/35\">",
"      Gertz ZM, Raina A, Saghy L, et al. Evidence of atrial functional mitral regurgitation due to atrial fibrillation: reversal with arrhythmia control. J Am Coll Cardiol 2011; 58:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/36\">",
"      Tanimoto M, Pai RG. Effect of isolated left atrial enlargement on mitral annular size and valve competence. Am J Cardiol 1996; 77:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/37\">",
"      Otsuji Y, Kumanohoso T, Yoshifuku S, et al. Isolated annular dilation does not usually cause important functional mitral regurgitation: comparison between patients with lone atrial fibrillation and those with idiopathic or ischemic cardiomyopathy. J Am Coll Cardiol 2002; 39:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/38\">",
"      Zhou X, Otsuji Y, Yoshifuku S, et al. Impact of atrial fibrillation on tricuspid and mitral annular dilatation and valvular regurgitation. Circ J 2002; 66:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/39\">",
"      Hsu LF, Ja&iuml;s P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004; 351:2373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/40\">",
"      Sun H, Gaspo R, Leblanc N, Nattel S. Cellular mechanisms of atrial contractile dysfunction caused by sustained atrial tachycardia. Circulation 1998; 98:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/41\">",
"      Schotten U, Ausma J, Stellbrink C, et al. Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation. Circulation 2001; 103:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/42\">",
"      Sanders P, Morton JB, Morgan JG, et al. Reversal of atrial mechanical stunning after cardioversion of atrial arrhythmias: implications for the mechanisms of tachycardia-mediated atrial cardiomyopathy. Circulation 2002; 106:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/43\">",
"      Louie EK, Liu D, Reynertson SI, et al. \"Stunning\" of the left atrium after spontaneous conversion of atrial fibrillation to sinus rhythm: demonstration by transesophageal Doppler techniques in a canine model. J Am Coll Cardiol 1998; 32:2081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/44\">",
"      Grimm RA, Stewart WJ, Maloney JD, et al. Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterization by simultaneous transesophageal echocardiography. J Am Coll Cardiol 1993; 22:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/45\">",
"      Mattioli AV, Castelli A, Andria A, Mattioli G. Clinical and echocardiographic features influencing recovery of atrial function after cardioversion of atrial fibrillation. Am J Cardiol 1998; 82:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/46\">",
"      Harjai K, Mobarek S, Abi-Samra F, et al. Mechanical dysfunction of the left atrium and the left atrial appendage following cardioversion of atrial fibrillation and its relation to total electrical energy used for cardioversion. Am J Cardiol 1998; 81:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/47\">",
"      Omran H, Jung W, Rabahieh R, et al. Left atrial chamber and appendage function after internal atrial defibrillation: a prospective and serial transesophageal echocardiographic study. J Am Coll Cardiol 1997; 29:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/48\">",
"      Fatkin D, Kuchar DL, Thorburn CW, Feneley MP. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for \"atrial stunning\" as a mechanism of thromboembolic complications. J Am Coll Cardiol 1994; 23:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/49\">",
"      Falcone RA, Morady F, Armstrong WF. Transesophageal echocardiographic evaluation of left atrial appendage function and spontaneous contrast formation after chemical or electrical cardioversion of atrial fibrillation. Am J Cardiol 1996; 78:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/50\">",
"      Shapiro EP, Effron MB, Lima S, et al. Transient atrial dysfunction after conversion of chronic atrial fibrillation to sinus rhythm. Am J Cardiol 1988; 62:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/51\">",
"      Stoddard MF, Dawkins PR, Prince CR, Longaker RA. Transesophageal echocardiographic guidance of cardioversion in patients with atrial fibrillation. Am Heart J 1995; 129:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/52\">",
"      Black IW, Fatkin D, Sagar KB, et al. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation. A multicenter study. Circulation 1994; 89:2509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/53\">",
"      Moreyra E, Finkelhor RS, Cebul RD. Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials. Am Heart J 1995; 129:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/54\">",
"      Gentile F, Elhendy A, Khandheria BK, et al. Safety of electrical cardioversion in patients with atrial fibrillation. Mayo Clin Proc 2002; 77:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/55\">",
"      Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol 1998; 82:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/56\">",
"      Oltrona L, Broccolino M, Merlini PA, et al. Activation of the hemostatic mechanism after pharmacological cardioversion of acute nonvalvular atrial fibrillation. Circulation 1997; 95:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/57\">",
"      Lip GY, Rumley A, Dunn FG, Lowe GD. Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation: effects of cardioversion to sinus rhythm. Int J Cardiol 1995; 51:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/58\">",
"      Abe, Y, Kim, J, Fukunami, M, et al. Evidence for the intravascular hyperclotting state induced by atrial fibrillation itself (abstract). J Am Coll Cardiol 1996; 27(Suppl A):35A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/59\">",
"      Upshaw CB Jr. Hemodynamic changes after cardioversion of chronic atrial fibrillation. Arch Intern Med 1997; 157:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/60\">",
"      Botkin SB, Dhanekula LS, Olshansky B. Outpatient cardioversion of atrial arrhythmias: efficacy, safety, and costs. Am Heart J 2003; 145:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/61\">",
"      Fung KC, Tan HC, Kritharides L. Acute reductions in ventricular myocardial tissue velocities after direct current cardioversion of atrial fibrillation. J Am Soc Echocardiogr 2003; 16:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/62\">",
"      Trouton TG, Allen JD, Young IS, et al. Altered cardiac oxygen extraction, lactate production and coronary blood flow after large dose transthoracic DC countershocks. Pacing Clin Electrophysiol 1993; 16:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/63\">",
"      Mayosi BM, Commerford PJ. Pulmonary edema following electrical cardioversion of atrial fibrillation. Chest 1996; 109:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/64\">",
"      Atwood JE, Myers J, Sullivan M, et al. The effect of cardioversion on maximal exercise capacity in patients with chronic atrial fibrillation. Am Heart J 1989; 118:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/65\">",
"      Gosselink AT, Crijns HJ, van den Berg MP, et al. Functional capacity before and after cardioversion of atrial fibrillation: a controlled study. Br Heart J 1994; 72:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/28/6601/abstract/66\">",
"      Gosselink AT, Bijlsma EB, Landsman ML, et al. Long-term effect of cardioversion on peak oxygen consumption in chronic atrial fibrillation. A 2-year follow-up. Eur Heart J 1994; 15:1368.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1041 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-60.18.131.125-10F4DE3033-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_28_6601=[""].join("\n");
var outline_f6_28_6601=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H267711034\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ADVERSE HEMODYNAMICS IN AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Contributing factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Rapid ventricular response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Irregular heart rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Atrial systole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Neurohumoral activation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6881060\">",
"      - Mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HEMODYNAMICS AFTER CONVERSION OF CHRONIC AF TO SINUS RHYTHM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Atrial stunning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Improved exercise capacity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6881162\">",
"      - Mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H267711034\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1041\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1041|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/4/14411\" title=\"table 1\">",
"      EHRA score of AF related symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=related_link\">",
"      Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=related_link\">",
"      Clinical manifestations and diagnosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12266?source=related_link\">",
"      Mechanisms of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_28_6602="Lamotrigine: Drug information";
var content_f6_28_6602=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lamotrigine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/40/41605?source=see_link\">",
"    see \"Lamotrigine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/34/3626?source=see_link\">",
"    see \"Lamotrigine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      LaMICtal&reg;;",
"     </li>",
"     <li>",
"      LaMICtal&reg; ODT&trade;;",
"     </li>",
"     <li>",
"      LaMICtal&reg; XR&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F186305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Lamotrigine&reg;;",
"     </li>",
"     <li>",
"      Auro-Lamotrigine;",
"     </li>",
"     <li>",
"      Lamictal&reg;;",
"     </li>",
"     <li>",
"      Mylan-Lamotrigine;",
"     </li>",
"     <li>",
"      PMS-Lamotrigine;",
"     </li>",
"     <li>",
"      ratio-Lamotrigine;",
"     </li>",
"     <li>",
"      Teva-Lamotrigine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F186348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticonvulsant, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F186309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Whole tablets should be used for dosing, round calculated dose down to the nearest whole tablet. Alternatively, a suspension may be prepared using immediate release tablets (see also Extemporaneous Prepared).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Lennox-Gastaut (adjunctive):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Immediate release formulation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Regimens",
"     <b>",
"      not containing",
"     </b>",
"     carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: Initial: Weeks 1 and 2: 25 mg once daily; Weeks 3 and 4: 50 mg once daily; Week 5 and beyond: Increase by 50 mg daily every 1-2 weeks; Usual maintenance: 225-375 mg daily in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Regimens",
"     <b>",
"      containing",
"     </b>",
"     valproic acid: Initial: Weeks 1 and 2: 25 mg every other day; Weeks 3 and 4: 25 mg once daily; Week 5 and beyond: Increase by 25-50 mg daily every 1-2 weeks; Usual maintenance: 100-200 mg daily (valproic acid alone) or 100-400 mg daily (valproic acid and other drugs that induce glucuronidation) in 1 or 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Regimens",
"     <b>",
"      containing",
"     </b>",
"     carbamazepine, phenytoin, phenobarbital, or primidone and without valproic acid: Initial: Weeks 1 and 2: 50 mg once daily; Weeks 3 and 4: 100 mg daily in 2 divided doses; Week 5 and beyond: Increase by 100 mg daily every 1-2 weeks; Usual maintenance: 300-500 mg daily in 2 divided doses; maximum daily dose: 700 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Partial seizures (adjunctive) and primary generalized tonic-clonic seizures (adjunctive):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Immediate release formulation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Regimens",
"     <b>",
"      not containing",
"     </b>",
"     carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: Initial: Weeks 1 and 2: 25 mg once daily; Weeks 3 and 4: 50 mg once daily; Week 5 and beyond: Increase by 50 mg daily every 1-2 weeks; Usual maintenance: 225-375 mg daily in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Regimens",
"     <b>",
"      containing",
"     </b>",
"     valproic acid: Initial: Weeks 1 and 2: 25 mg every other day; Weeks 3 and 4: 25 mg once daily; Week 5 and beyond: Increase by 25-50 mg daily every 1-2 weeks; Usual maintenance: 100-200 mg daily (valproic acid alone) or 100-400 mg daily (valproic acid and other drugs that induce glucuronidation) in 1 or 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Regimens",
"     <b>",
"      containing",
"     </b>",
"     carbamazepine, phenytoin, phenobarbital, or primidone and without valproic acid: Initial: Weeks 1 and 2: 50 mg once daily; Weeks 3 and 4: 100 mg daily in 2 divided doses; Week 5 and beyond: Increase by 100 mg daily every 1-2 weeks; Usual maintenance: 300-500 mg daily in 2 divided doses; maximum daily dose: 700 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release formulation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Regimens",
"     <b>",
"      not containing",
"     </b>",
"     carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: Initial: Weeks 1 and 2: 25 mg once daily; Weeks 3 and 4: 50 mg once daily; Week 5: 100 mg once daily; Week 6: 150 mg once daily; Week 7: 200 mg once daily; Week 8 and beyond : Dose increases should not exceed 100 mg daily at weekly intervals; Usual maintenance: 300-400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Regimens",
"     <b>",
"      containing",
"     </b>",
"     valproic acid: Initial: Weeks 1 and 2: 25 mg every other day; Weeks 3 and 4: 25 mg once daily; Week 5: 50 mg once daily; Week 6: 100 mg once daily; Week 7: 150 mg once daily; Week 8 and beyond : Dose increases should not exceed 100 mg daily at weekly intervals; Usual maintenance: 200-250 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Regimens",
"     <b>",
"      containing",
"     </b>",
"     carbamazepine, phenytoin, phenobarbital, or primidone and without valproic acid: Initial: Weeks 1 and 2: 50 mg once daily; Weeks 3 and 4: 100 mg once daily; Week 5: 200 mg once daily; Week 6: 300 mg once daily; Week 7: 400 mg once daily; Week 8 and beyond : Dose increases should not exceed 100 mg daily at weekly intervals; Usual maintenance: 400-600 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <span style=\"text-decoration: underline\">",
"      Conversion strategy from adjunctive therapy with valproic acid to monotherapy with lamotrigine:",
"     </span>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release formulation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     - Initiate and titrate as per escalation recommendations for adjunctive therapy to a lamotrigine dose of 200 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     - Then taper valproic acid dose in decrements of not &gt;500 mg/day/week to a valproic acid dosage of 500 mg daily; this dosage should be maintained for 1 week. The lamotrigine dosage should then be increased to 300 mg daily while valproic acid is simultaneously decreased to 250 mg daily; this dosage should be maintained for 1 week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     - Valproic acid may then be discontinued, while the lamotrigine dose is increased by 100 mg daily at weekly intervals to achieve a lamotrigine maintenance dose of 500 mg daily in 2 divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release formulation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     - Initiate and titrate as per escalation recommendations for adjunctive therapy to a lamotrigine dose of 150 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     - Then taper valproic acid dose in decrements of not &gt;500 mg/day/week to a valproic acid dose of 500 mg daily; this dosage should be maintained for 1 week. The lamotrigine dosage should then be increased to 200 mg daily while valproic acid is simultaneously decreased to 250 mg daily; this dosage should be maintained for 1 week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     - Valproic acid may then be discontinued, while the lamotrigine dose is increased to achieve a maintenance dosage range of 250-300 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <span style=\"text-decoration: underline\">",
"      Conversion strategy from adjunctive therapy with carbamazepine, phenytoin, phenobarbital, or primidone to monotherapy with lamotrigine:",
"     </span>",
"     <i>",
"      Immediate release formulation and extended release formulation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     - Initiate and titrate as per escalation recommendations for adjunctive therapy to a lamotrigine dose of 500 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     - Concomitant enzyme-inducing AED should then be withdrawn by 20% decrements each week over a 4-week period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     - Following withdrawal of the enzyme-inducing AED (eg, ~2 weeks later for extended release; 1 week later for immediate release), the dosage of lamotrigine may be tapered in decrements of not &gt;100 mg daily at 1-week intervals to achieve a maintenance dosage range of 250-300 mg once daily (extended release) or 200 mg daily (immediate release) as clinically indicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <span style=\"text-decoration: underline\">",
"      Conversion strategy from adjunctive therapy with AED other than carbamazepine, phenytoin, phenobarbital, primidone or valproic acid to monotherapy with lamotrigine:",
"     </span>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release formulation:",
"     </i>",
"     No specific guidelines available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release formulation:",
"     </i>",
"     Initiate and titrate as per escalation recommendations for adjunctive therapy to a lamotrigine dose of 250-300 mg daily. Concomitant AED should then be withdrawn by 20% decrements each week over a 4-week period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <span style=\"text-decoration: underline\">",
"      Conversion from immediate release to extended release (Lamictal&reg; XR&trade;):",
"     </span>",
"     Initial dose of the extended release tablet should match the total daily dose of the immediate-release formulation. Adjust dose as needed within the recommended dosing guidelines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Bipolar disorder:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release formulation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Regimens",
"     <b>",
"      not containing",
"     </b>",
"     carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: Initial: Weeks 1 and 2: 25 mg once daily; Weeks 3 and 4: 50 mg once daily; Week 5: 100 mg once daily; Week 6 and maintenance: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Regimens",
"     <b>",
"      containing",
"     </b>",
"     valproic acid: Initial: Weeks 1 and 2: 25 mg every other day; Weeks 3 and 4: 25 mg once daily; Week 5: 50 mg once daily; Week 6 and maintenance: 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Regimens",
"     <b>",
"      containing",
"     </b>",
"     carbamazepine, phenytoin, phenobarbital, or primidone and without valproic acid: Initial: Weeks 1 and 2: 50 mg once daily; Weeks 3 and 4: 100 mg daily in divided doses; Week 5: 200 mg daily in divided doses; Week 6: 300 mg daily in divided doses; Maintenance: up to 400 mg daily in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adjustment following discontinuation of psychotropic medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Discontinuing valproic acid with current dose of lamotrigine 100 mg daily: 150 mg daily for week 1, then increase to 200 mg daily beginning week 2",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Discontinuing carbamazepine, phenytoin, phenobarbital, primidone, or rifampin with current dose of lamotrigine 400 mg daily: 400 mg daily for week 1, then decrease to 300 mg daily for week 2, then decrease to 200 mg daily beginning week 3",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Uncontrolled epilepsy (adjunctive) or Lennox-Gastaut syndrome (adjunctive):",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     AED that induce lamotrigine glucuronidation include carbamazepine, phenytoin, phenobarbital, and primidone. Antiepileptic agents that do not induce or inhibit lamotrigine glucuronidation include oxcarbazepine, felbamate, levetiracetam, gabapentin, topiramate, zonisamide, pregabalin. Valproic acid inhibits lamotrigine glucuronidation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Regimens",
"     <b>",
"      containing",
"     </b>",
"     inducers of lamotrigine glucuronidation and valproic acid or regimens not containing agents that induce or inhibit lamotrigine glucuronidation: Initial: Weeks 1 and 2: 25 mg once daily; Weeks 3 and 4: 25 mg twice daily; Week 5 and beyond: Increase dose by 25-50 mg every 1-2 weeks until maintenance dose established (usual maintenance dose: 100-200 mg daily in 2 divided doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Regimens",
"     <b>",
"      containing",
"     </b>",
"     inducers of lamotrigine glucuronidation and without valproic acid: Initial: Weeks 1 and 2: 50 mg once daily; Weeks 3 and 4: 50 mg twice daily; Week 5 and beyond: Increase dose by 100 mg every 1-2 weeks until maintenance dose established (usual maintenance dose: 300-500 mg daily in 2 divided doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Conversion from adjunctive therapy with concomitant AEDs for epilepsy to lamotrigine monotherapy: Decrease dose of concomitant antiepileptic agent by ~20% of original dose every week for 5 weeks (slower taper may be considered if clinically indicated). Lamotrigine dosage adjustments during this period should be determined by changes in lamotrigine pharmacokinetics due to withdrawal of the concomitant AED, and by the clinical response of patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Additional considerations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Discontinuing therapy:",
"     </b>",
"     Decrease dose by ~50% per week, over at least 2 weeks unless safety concerns require a more rapid withdrawal. Discontinuing carbamazepine, phenytoin, phenobarbital, primidone, or rifampin  should prolong the half-life of lamotrigine; discontinuing valproic acid should shorten the half-life of lamotrigine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Restarting therapy after discontinuation:",
"     </b>",
"     If lamotrigine has been withheld for &gt;5 half-lives, consider restarting according to initial dosing recommendations.",
"     <b>",
"      Note:",
"     </b>",
"     Concomitant medications may affect the half-life of lamotrigine; consider pharmacokinetic interactions when restarting therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment with estrogen-containing hormonal contraceptives:",
"     </b>",
"     Follow initial lamotrigine dosing guidelines, maintenance dose should be adjusted as follows, based on concomitant medications:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Patients taking concomitant carbamazepine, phenytoin, phenobarbital, primidone or rifampin: No dosing adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Patients",
"     <b>",
"      not",
"     </b>",
"     taking concomitant carbamazepine, phenytoin, phenobarbital, primidone or rifampin: Lamotrigine maintenance dose may need increased by twofold over target dose. If already taking a stable dose of lamotrigine and starting contraceptive, maintenance dose may need increased by twofold. Dose increases should start when contraceptive is started and titrated to clinical response increasing no more rapidly than 50-100 mg daily every week. Gradual increases of lamotrigine plasma levels may occur during the inactive &ldquo;pill-free&rdquo; week and will be greater when dose increases are made the week before. If increased adverse events consistently occur during &ldquo;pill-free&rdquo; week, overall maintenance dose adjustments may be required. When discontinuing estrogen-containing  hormonal contraceptive, dose of lamotrigine may need decreased by as much as 50%; do not decrease by more than 25% of total daily dose over a 2-week period unless clinical response or plasma levels indicate otherwise. Dose adjustments during &ldquo;pill-free&rdquo; week are not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F186329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/34/3626?source=see_link\">",
"      see \"Lamotrigine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Extended release tablets not FDA approved for use in children &le;12 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Lennox-Gastaut syndrome (adjunctive), primary generalized tonic-clonic seizures (adjunctive), or partial seizures (adjunctive):",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Whole tablets should be used for dosing, round calculated dose down to the nearest whole tablet. Alternatively, a suspension may be prepared using immediate release tablets (see also Extemporaneous Prepared). Children &lt;30 kg will likely require maintenance doses to be increased by as much as 50% based on clinical response regardless of regimen below:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-12 years:",
"     <i>",
"      Immediate release formulation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Regimens",
"     <b>",
"      not containing",
"     </b>",
"     carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: Initial: Weeks 1 and 2: 0.3 mg/kg/day in 1-2 divided doses; Weeks 3 and 4: 0.6 mg/kg/day in 2 divided doses; Week 5 and beyond: Increase by 0.6 mg/kg/day every 1-2 weeks; Usual maintenance: 4.5-7.5 mg/kg/day (maximum: 300 mg daily) in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Regimens",
"     <b>",
"      containing",
"     </b>",
"     valproic acid : Initial: Weeks 1 and 2: 0.15 mg/kg/day in 1-2 divided doses (if calculated dose is equal to or rounds down to 1 mg daily, give 2 mg every other day instead); Weeks 3 and 4: 0.3 mg/kg/day in 1-2 divided doses; Week 5 and beyond: Increase by 0.3 mg/kg/day every 1-2 weeks; Usual maintenance: 1-5 mg/kg/day (maximum: 200 mg daily) in 1 or 2 divided doses or 1-3 mg/kg/day (maximum: 200 mg daily) (valproic acid alone)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Regimens",
"     <b>",
"      containing",
"     </b>",
"     carbamazepine, phenytoin, phenobarbital, or primidone and without valproic acid: Initial: Weeks 1 and 2: 0.6 mg/kg/day in 2 divided doses; Weeks 3 and 4: 1.2 mg/kg/day in 2 divided doses; Week 5 and beyond:  Increase by 1.2 mg/kg/day every 1-2 weeks; Usual maintenance: 5-15 mg/kg/day (maximum: 400 mg daily) in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents &gt;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Conversion from adjunctive therapy with a single AED (eg, carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid) for partial seizures to monotherapy with lamotrigine:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release formulation:",
"     </i>",
"     Adolescents &ge;16 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release formulation:",
"     </i>",
"     Adolescents &ge;13 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Lennox-Gastaut syndrome (adjunctive therapy):",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Whole tablets should be used for dosing, round calculated dose down to the nearest whole tablet. Alternatively, a suspension may be prepared using immediate release tablets (see also Extemporaneous preparations field). Several weeks to months may be required to achieve individualized maintenance dose. Use is not recommended in children &lt;9 kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children &le;12 years (and &ge;9 kg):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Regimens",
"     <b>",
"      containing",
"     </b>",
"     valproic acid regardless of any other concomitant medication: Initial: Weeks 1 and 2: 0.15 mg/kg once daily (if calculated dose is equal to or rounds down to 1 mg daily, give 2 mg every other day instead); Weeks 3 and 4: 0.3 mg/kg once daily; Week 5 and beyond: Increase dose by 0.3 mg/kg every 1-2 weeks (usual maintenance dose: 1-5 mg/kg daily in 1 or 2 divided doses) up to a maximum dose of 200 mg daily.",
"     <b>",
"      Note:",
"     </b>",
"     Alternatively, refer to manufacturer&rsquo;s labeling for recommended weight-based rounding regimen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Regimens",
"     <b>",
"      containing",
"     </b>",
"     carbamazepine, phenytoin, phenobarbital, primidone or other drugs that induce glucuronidation and without valproic acid: Initial: Weeks 1 and 2: 0.3 mg/kg twice daily; Weeks 3 and 4: 0.6 mg/kg twice daily; Week 5 and beyond: Increase dose by 1.2 mg/kg every 1-2 weeks (usual maintenance dose: 2.5-7.5 mg/kg twice daily) up to a maximum dose of 400 mg daily.",
"     <b>",
"      Note:",
"     </b>",
"     When necessary, round doses down to closest 5 mg interval (eg, calculated dose &gt;5 mg and &lt;10 mg would be rounded to 5 mg; calculated dose &gt;10 mg and &lt;15 mg would be rounded to 10 mg). For week 5 and beyond, dose increases made every 1-2 weeks should not exceed previous daily dose administered in week 4 (eg, if week 4 dose was 20 mg daily than dose increase in week 5 or beyond should not exceed 20 mg daily). Manufacturer labeling suggests that insufficient data exists to support weight based dosing in patients &gt;59 kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents &gt;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Uncontrolled epilepsy (adjunctive therapy); conversion from adjunctive therapy with concomitant AEDs for epilepsy to monotherapy with lamotrigine:",
"     </b>",
"     Adolescents &ge;16 years: Refer to adult dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Additional considerations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Discontinuing therapy:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Restarting therapy after discontinuation:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment with estrogen-containing hormonal contraceptives:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F186310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F186311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreased maintenance dosage may be effective in patients with significant renal impairment; has not been adequately studied; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F186312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild impairment: No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate-to-severe impairment without ascites: Decrease initial, escalation, and maintenance doses by ~25%; adjust according to clinical response and tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate-to-severe impairment with ascites: Decrease initial, escalation, and maintenance doses by ~50%; adjust according to clinical response and tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild and moderate impairment (Child-Pugh classes A and B): Reduce initial, escalation, and maintenance dosing by ~50%; adjust according to clinical response and tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment (Child-Pugh class C): Reduce initial, escalation, and maintenance dosing by ~75%; adjust according to clinical response and tolerance.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F186277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 100 mg, 150 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg;: 25 mg, 100 mg, 150 mg, 200 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [combination package (each unit-dose starter kit contains)]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg;: 25 mg (84s) [white tablets] and 100 mg (14s) [peach tablets] [scored; green kit; for patients taking carbamazepine, phenytoin, phenobarbital, primidone, or rifampin and",
"     <b>",
"      not",
"     </b>",
"     taking valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg;: 25 mg (42s) [white tablets] and 100 mg (7s) [peach tablets] [scored; orange kit; for patients",
"     <b>",
"      not",
"     </b>",
"     taking carbamazepine, phenytoin, phenobarbital, primidone, rifampin, or valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [each unit-dose starter kit contains]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg;: 25 mg [scored; blue kit; for patients taking valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable/dispersible, oral: 5 mg, 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg;: 2 mg [black currant flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg;: 5 mg [scored; black currant flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg;: 25 mg [black currant flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 25 mg, 50 mg, 100 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg; XR&trade;: 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral [combination package (each patient titration kit contains)]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg; XR&trade;: 25 mg (21s) [yellow/white tablets] and 50 mg (7s) [green/white tablets] [blue XR kit, for patients taking valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg; XR&trade;: 50 mg (14s) [green/white tablets], 100 mg (14s) [orange/white tablets], and 200 mg (7s) [blue/white tablets] [green XR kit, for patients taking carbamazepine, phenytoin, phenobarbital, primidone, and",
"     <b>",
"      not",
"     </b>",
"     taking valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg; XR&trade;: 25 mg (14s) [yellow/white tablets], 50 mg (14s) [green/white tablets], and 100 mg (7s) [orange/white tablets] [orange XR kit, for patients",
"     <b>",
"      not",
"     </b>",
"     taking carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg; ODT&trade;: 25 mg, 50 mg, 100 mg, 200 mg [cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral [combination package (each patient titration kit contains)]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg; ODT&trade;: 25 mg (21s) and 50 mg (7s) [cherry flavor; blue kit, for patients taking valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg; ODT&trade;: 50 mg (42s) and 100 mg (14s) [cherry flavor; green kit, for patients taking carbamazepine, phenytoin, phenobarbital, primidone, or rifampin and",
"     <b>",
"      not",
"     </b>",
"     taking valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaMICtal&reg; ODT&trade;: 25 mg (14s), 50 mg (14s), and 100 mg (7s) [cherry flavor; orange kit, for patients",
"     <b>",
"      not",
"     </b>",
"     taking carbamazepine, phenytoin, phenobarbital, primidone, rifampin, or valproic acid]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F186262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes orally disintegrating tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information, and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Lamictal&reg;, Lamictal&reg; ODT&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM152835.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM152835.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Lamictal&reg; XR&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM166013.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM166013.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F186282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses should be rounded down to the nearest whole tablet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lamictal&reg; chewable/dispersible tablets: May be chewed, dispersed in water or diluted fruit juice, or swallowed whole. To disperse tablets, add to a small amount of liquid (just enough to cover tablet); let sit ~1 minute until dispersed; swirl solution and consume immediately. Do not administer partial amounts of liquid. If tablets are chewed, a small amount of water or diluted fruit juice should be used to aid in swallowing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lamictal&reg; ODT&trade;: Place tablets on tongue and move around in the mouth. Tablets will dissolve rapidly and can be swallowed with or without food or water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lamictal&reg; XR&trade;: Administer without regard to meals. Swallow whole; do not chew, crush, or cut.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F186281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     U.S. labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Immediate release: Adjunctive therapy in the treatment of generalized seizures of Lennox-Gastaut syndrome, primary generalized tonic-clonic seizures, and partial seizures; conversion to monotherapy in patients with partial seizures who are receiving treatment with a single antiepileptic drug (AED) (specifically carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid); maintenance treatment of bipolar I disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extended release: Adjunctive therapy for primary generalized tonic-clonic seizures and partial seizures (with or without secondary generalization); conversion to monotherapy in patients with partial seizures who are receiving treatment with a single antiepileptic drug AED",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canadian labeling: Immediate release: Adjunctive therapy for epilepsy uncontrolled by conventional therapy; monotherapy of epilepsy following withdrawal of concurrent antiepileptic agents; adjunctive therapy for Lennox-Gastaut syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F186355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       LamoTRIgine may be confused with labetalol, LamISIL&reg;, lamiVUDine, levothyroxine, Lomotil&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       LaMICtal&reg; may be confused with LamISIL&reg;, Lomotil&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Potential exists for medication errors to occur among different formulations of LaMICtal&reg; (tablets, extended release tablets, orally disintegrating tablets, and chewable/dispersible tablets). Patients should be instructed to visually inspect tablets dispensed to verify receiving the correct medication and formulation. The medication guide includes illustrations to aid in tablet verification.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lamictal [U.S., Canada, and multiple international markets] may be confused with Ludiomil brand name for maprotiline [multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lamotrigine [U.S., Canada, and multiple international markets] may be confused with Ludiomil brand name for maprotiline [multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F186346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages reported in adults on monotherapy for epilepsy or bipolar disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Nausea (7% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (5%), peripheral edema (2% to 5%), edema (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Insomnia (5% to 10%), somnolence (9%), fatigue (8%), coordination impaired (7%), dizziness (7%), anxiety (5%), pain (5%), ataxia (2% to 5%), irritability (2% to 5%), suicidal ideation (2% to 5%), agitation (1% to 5%), amnesia (1% to 5%), depression (1% to 5%), dream abnormality (1% to 5%), emotional lability (1% to 5%), fever (1% to 5%), hypoesthesia (1% to 5%), migraine (1% to 5%), thought abnormality (1% to 5%), confusion (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (nonserious: 7%), dermatitis (2% to 5%), dry skin (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea (5%), libido increased (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (5% to 9%), dyspepsia (7%), abdominal pain (6%), xerostomia (2% to 6%), constipation (5%), weight loss (5%), anorexia (2% to 5%), peptic ulcer (2% to 5%), rectal hemorrhage (2% to 5%), flatulence (1% to 5%), weight gain (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary frequency (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (8%), weakness (2% to 5%), arthralgia (1% to 5%), myalgia (1% to 5%), neck pain (1% to 5%), paresthesia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Nystagmus (2% to 5%), vision abnormal (2% to 5%), amblyopia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (7%), cough (5%), pharyngitis (5%), bronchitis (2% to 5%), dyspnea (2% to 5%), epistaxis (2% to 5%), sinusitis (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (5%), diaphoresis (2% to 5%), reflexes increased/decreased (2% to 5%), dyspraxia (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%: Any indication (limited to important or life-threatening): Accommodation abnormality, agranulocytosis, alcohol intolerance, allergic reaction, alopecia, anemia, angina, angioedema, aphasia, aplastic anemia, apnea, appetite increased, arthritis, aseptic meningitis, atrial fibrillation, bruising, cerebellar syndrome, cerebral sinus thrombosis, cerebrovascular accident, chills, choreoathetosis, CNS depression/stimulation, conjunctivitis, deafness, deep thrombophlebitis, delirium, delusions,  dermatitis (exfoliative, fungal), disseminated intravascular coagulation, dysphagia, dysphoria, dystonia, ECG abnormality, ejaculation abnormal, eructation, erythema multiforme, esophagitis, euphoria, extrapyramidal syndrome, flushing, gastritis, gingivitis, goiter, hallucinations, hematuria, hemiplegia, hemolytic anemia, hemorrhage, hepatitis, hiccup, hirsutism, hot flashes, hyperalgesia, hyperglycemia, hypersensitivity reactions, hypertension, hyperventilation, hypokinesia, hypothyroidism, hypotonia, impotence, kidney failure (acute), leg cramps, leukopenia, liver function tests abnormal, lupus-like reaction, lymphadenopathy, maculopapular rash, menorrhagia, MI, mouth ulceration, movement disorder, multiorgan failure, muscle spasm, myasthenia, neuralgia, neurosis, neutropenia, orthostatic hypotension, palpitation, pancreatitis, pancytopenia, paralysis, parkinsonian exacerbation, peripheral neuritis, photophobia, polyuria, progressive immunosuppression, pruritus, pure red cell aplasia, rhabdomyolysis, salivation increased, skin discoloration, status epilepticus, Stevens-Johnson syndrome, sudden unexplained death in epilepsy (SUDEP), suicidal behavior, suicide, syncope, tachycardia, taste loss/perversion, thrombocytopenia, tic, tinnitus, tongue edema, toxic epidermal necrolysis, twitching, urinary incontinence, urticaria, vasculitis, vasodilation, withdrawal seizures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Also observed: Rash requiring hospitalization: Children &lt;16 years 0.8% (epilepsy adjunctive therapy), 1.2 % (with concurrent valproic acid use); Adults 0.3% (epilepsy adjunctive therapy), 0.13% (epilepsy monotherapy), 1% (with concurrent valproic acid use), 0.8% (bipolar disorder, monotherapy)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F186286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lamotrigine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F186266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aseptic meningitis: Increased risk of developing aseptic meningitis has been reported; symptoms (eg, headache, nuchal rigidity, fever, nausea/vomiting, rash, photophobia) have generally occurred within 1-45 days following therapy initiation. In some cases, new onset hepatic, renal and/or other organ involvement has also occurred with symptoms, possibly suggesting aseptic meningitis is associated with a hypersensitivity reaction (eg, anticonvulsant hypersensitivity syndrome). Symptoms of aseptic meningitis generally resolve following discontinuation.  In some cases, re-exposure has resulted in a rapid return of symptoms (often more severe).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: A spectrum of hematologic effects have been reported with use (eg, neutropenia, leukopenia, thrombocytopenia, pancytopenia, anemias, and rarely, aplastic anemia and pure red cell aplasia); patients with a previous history of adverse hematologic reaction to any drug may be at increased risk. Early detection of hematologic change is important; advise patients of early signs and symptoms including fever, sore throat, mouth ulcers, infections, easy bruising, petechial or purpuric hemorrhage. May be associated with hypersensitivity syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Multiorgan hypersensitivity reactions (drug reaction with eosinophilia and systemic symptoms [DRESS]): Potentially serious, sometimes fatal, multiorgan hypersensitivity reactions (DRESS) have been reported with some antiepileptic drugs (rare). Symptoms may include fever, rash, and/or lymphadenopathy; monitor for signs and symptoms of possible disparate manifestations associated with lymphatic, hepatic, renal, and/or hematologic organ systems. Early symptoms of hypersensitivity reaction (eg, lymphadenopathy, fever) may occur without rash; discontinuation and conversion to alternate therapy may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Severe and potentially life-threatening skin rashes requiring hospitalization have been reported; incidence of serious rash is higher in pediatric patients than adults; risk may be increased by coadministration with valproic acid, higher than recommended starting doses, and exceeding recommended dose titration.",
"     </b>",
"     The majority of cases occur in the first 8 weeks; however, isolated cases may occur after prolonged treatment or in patients without these risk factors; discontinue at first sign of rash and do not reinitiate therapy unless rash is clearly not drug related. Rare cases of Stevens-Johnson syndrome, toxic epidermal necrolysis, and angioedema have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hormonal contraceptives: May cause a decrease in lamotrigine levels; dose adjustment of the lamotrigine maintenance dose may be required when initiating or discontinuing estrogen-containing oral contraceptives.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Valproic acid: May cause an increase in lamotrigine levels requiring dose adjustment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children are at increased risk for developing serious skin rashes during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Bipolar disorder use: Patients treated for bipolar disorder should be monitored closely for clinical worsening or suicidality; prescriptions should be written for the smallest quantity consistent with good patient care.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Medication error potential: Medication errors have occurred; potential for medication errors with similar-sounding medications and between different lamotrigine formulations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Melanin binding: Binds to melanin and may accumulate in the eye and other melanin-rich tissues; the clinical significance of this is not known.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monotherapy: Safety and efficacy have not been established for use as initial monotherapy, conversion to monotherapy from antiepileptic drugs (AED) other than carbamazepine, phenytoin, phenobarbital, primidone or valproic acid or conversion to monotherapy from two or more AEDs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal. Taper over at least 2 weeks if possible.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F186271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of LamoTRIgine. Management: See lamotrigine prescribing information for specific age-dependent dosing guidelines regarding concurrent use with a barbiturate, as well as for adjusting lamotrigine dosing if concurrent barbiturate therapy is discontinued.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: LamoTRIgine may enhance the adverse/toxic effect of CarBAMazepine. CarBAMazepine may increase the metabolism of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May decrease the serum concentration of LamoTRIgine. Management: Monitor for increased serum concentrations/effects of lamotrigine in patients in whom a hormonal contraceptive is discontinued/dose decreased (this includes during a pill-free week). A reduced dosage of lamotrigine may be needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): LamoTRIgine may decrease the serum concentration of Contraceptives (Progestins).  Management: Women using progestin-only &ldquo;minipill&rdquo; products may be at risk for contraceptive failure; it is unclear if other progestin-containing products would be significantly impacted.  Alternative, non-hormonal, means of contraception are recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: LamoTRIgine may enhance the adverse/toxic effect of Desmopressin. LamoTRIgine may enhance the therapeutic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May enhance the adverse/toxic effect of LamoTRIgine. Divalproex may increase the serum concentration of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: LamoTRIgine may increase the serum concentration of MetFORMIN.  Management: The lamotrigine Canadian product monograph states that coadministration of these drugs is not recommended.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: LamoTRIgine may enhance the sedative effect of OLANZapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of LamoTRIgine. Management: Adjust dose per lamotrigine prescribing information guidelines during primidone treatment.  Monitor for decreased concentration/effect if primidone is initiated/dose increased or increased concentration/effect if primidone is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procainamide: LamoTRIgine may increase the serum concentration of Procainamide.  Management: Consider monitoring for increased procainamide concentrations and/or systemic effects in patients receiving procainamide with lamotrigine.  The lamotrigine Canadian product monograph states that coadministration of these agents is not recommended.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of LamoTRIgine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May decrease the serum concentration of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May enhance the adverse/toxic effect of LamoTRIgine. Valproic Acid may increase the serum concentration of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F186300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Has no effect on absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid evening primrose (seizure threshold decreased).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F186273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F186289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lamotrigine has been found to decrease folate concentrations in animal studies. Teratogenic effects in animals were not observed. Lamotrigine crosses the human placenta and can be measured in the plasma of exposed newborns. Preliminary data from the North American Antiepileptic Drug Pregnancy Registry (NAAED) suggest an increased incidence of cleft lip and/or cleft palate following first trimester exposure. Healthcare providers may enroll patients in the Lamotrigine Pregnancy Registry by calling (800) 336-2176. Patients may enroll themselves in the NAAED registry by calling (888) 233-2334. Additional information is available at www.aedpregnancyregistry.org. Dose of lamotrigine may need adjustment during pregnancy to maintain clinical response; lamotrigine serum levels may decrease during pregnancy and return to prepartum levels following delivery. Monitor frequently during pregnancy, following delivery, and when adding or discontinuing combination hormonal contraceptives.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F186316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3345147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lamotrigine is found in breast milk. In one study, the relative dose to the infant was 9% (range: 2% to 20%) of the weight-adjusted maternal dose. Lamotrigine was measurable in the plasma of nursing infants; adverse events were not observed.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F186288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (LaMICtal Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (30): $0.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $716.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $768.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (LamoTRIgine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $305.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $319.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (LaMICtal ODT Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 (21)-50 (7) mg (28): $254.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 &amp; 50 &amp; 100 mg (35): $363.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 (42)-100(14) mg (56): $727.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (LaMICtal Starter Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 (35) mg (35): $259.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 (42)-100 (7) mg (49): $370.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (LaMICtal XR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 (21)-50 (7) mg (28): $254.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 &amp; 50 &amp; 100 mg (35): $363.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 &amp; 100 &amp; 200 mg (35): $727.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (LaMICtal XR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $218.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $436.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $467.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (30): $498.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (30): $679.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $747.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (LamoTRIgine ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $196.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $392.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $420.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (30): $448.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (30): $611.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $673.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (LaMICtal ODT Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $218.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $233.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $249.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (30): $297.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (LaMICtal Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $740.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $845.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (60): $555.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (60): $605.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (LamoTRIgine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $415.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $475.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (60): $312.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (60): $340.15",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F186275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum levels of concurrent anticonvulsants, LFTs, renal function, hypersensitivity reactions (especially rash); seizure, frequency and duration; suicidality (eg, suicidal thoughts, depression, behavioral changes); signs/symptoms of aseptic meningitis",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F186278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A therapeutic serum concentration range has not been established for lamotrigine. Dosing should be based on therapeutic response. Lamotrigine plasma concentrations of 0.25-29.1 mcg/mL have been reported in the literature.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F186291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Elmendos (AU);",
"     </li>",
"     <li>",
"      Labicitin (KP);",
"     </li>",
"     <li>",
"      Lamdra SBK (MX);",
"     </li>",
"     <li>",
"      Lamepil (IN);",
"     </li>",
"     <li>",
"      Lameptil (KP);",
"     </li>",
"     <li>",
"      Lametec (CO);",
"     </li>",
"     <li>",
"      Lamiart (KP);",
"     </li>",
"     <li>",
"      Lamictal (AE, AR, AT, AU, BB, BD, BE, BG, BH, BM, BO, BR, BS, BZ, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, GY, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IT, JM, JO, JP, KP, KW, LB, LU, LY, MT, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PR, PT, PY, QA, RU, SA, SE, SG, SK, SR, SV, SY, TH, TR, TT, TW, UY, VE, YE);",
"     </li>",
"     <li>",
"      Lamidus (AU, TW);",
"     </li>",
"     <li>",
"      Lamitor (PH);",
"     </li>",
"     <li>",
"      Lamitor OD (PH);",
"     </li>",
"     <li>",
"      Lamodex (IL);",
"     </li>",
"     <li>",
"      Lamogin (CO, TW);",
"     </li>",
"     <li>",
"      Lamogine (IL);",
"     </li>",
"     <li>",
"      Lamotrin (HK);",
"     </li>",
"     <li>",
"      Lamotrix (MY);",
"     </li>",
"     <li>",
"      Latrigine (TW);",
"     </li>",
"     <li>",
"      Mogine (NZ);",
"     </li>",
"     <li>",
"      Neurium (BR);",
"     </li>",
"     <li>",
"      Protalgine (MX);",
"     </li>",
"     <li>",
"      Seaze (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F186265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A triazine derivative which inhibits release of glutamate (an excitatory amino acid) and inhibits voltage-sensitive sodium channels, which stabilizes neuronal membranes. Lamotrigine has weak inhibitory effect on the 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     receptor;",
"     <i>",
"      in vitro",
"     </i>",
"     inhibits dihydrofolate reductase.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F186285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Immediate release: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.9-1.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~55%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic and renal; metabolized primarily by glucuronic acid conjugation to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Immediate release: 98%;",
"     <b>",
"      Note:",
"     </b>",
"     AUCs were similar for immediate release and extended release preparations in patients receiving nonenzyme-inducing AEDs. In subjects receiving concomitant enzyme-inducing AEDs, bioavailability of extended release product was ~21% lower than immediate release product; in some of these subjects, a decrease in AUC of up to 70% was observed when switching from immediate release to extended release tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Immediate release: Adults: 25-33 hours, Elderly: 25-43 hours; Extended release: Similar to immediate release",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Concomitant valproic acid therapy: 48-70 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Concomitant phenytoin, phenobarbital, primidone, or carbamazepine therapy: 13-14 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chronic renal failure: 43 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: 13 hours during dialysis; 57 hours between dialysis (~20% of a dose is eliminated in a 4-hour dialysis session)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic impairment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild: 26-66 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Moderate: 28-116 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe without ascites: 56-78 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe with ascites: 52-148 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Immediate release: 1-1.5 hours; Extended release: 4-11 hours (dependent on adjunct therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (94%, ~90% as glucuronide conjugates and ~10% unchanged); feces (2%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/28/6602/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Battino D, Estienne M, and Avanzini G, &ldquo;Clinical Pharmacokinetics of Antiepileptic Drugs in Paediatric Patients: Part II. Phenytoin, Carbamazepine, Sulthiame, Lamotrigine, Vigabatrin, Oxcarbazepine, and Felbamate,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1995, 29(5):341-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/28/6602/abstract-text/8582119/pubmed\" id=\"8582119\" target=\"_blank\">",
"        8582119",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Besag FM, Wallace SJ, Dulac O, et al, &ldquo;Lamotrigine for the Treatment of Epilepsy in Childhood,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1995, 127(6):991-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/28/6602/abstract-text/8523205/pubmed\" id=\"8523205\" target=\"_blank\">",
"        8523205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brodie MJ, &ldquo;Lamotrigine,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1992, 339(8806):1397-400.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/28/6602/abstract-text/1350815/pubmed\" id=\"1350815\" target=\"_blank\">",
"        1350815",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burstein AH, &ldquo;Lamotrigine,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1995, 15(2):129-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/28/6602/abstract-text/7624259/pubmed\" id=\"7624259\" target=\"_blank\">",
"        7624259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Calabrese JR, Suppes T, Bowden CL, et al, &ldquo;A Double-Blind, Placebo-Controlled, Prophylaxis Study of Lamotrigine in Rapid-Cycling Bipolar Disorder,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2000, 61(11):841-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/28/6602/abstract-text/11105737/pubmed\" id=\"11105737\" target=\"_blank\">",
"        11105737",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Haan GJ, Edelbroek P, Segers J, et al, &ldquo;Gestation-Induced Changes in Lamotrigine Pharmacokinetics: A monotherapy Study,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2004, 63(3):571-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/28/6602/abstract-text/15304599/pubmed\" id=\"15304599\" target=\"_blank\">",
"        15304599",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dooley J, Camfield P, Gordon K, et al, &ldquo;Lamotrigine-Induced Rash in Children,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1996, 46(1):240-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/28/6602/abstract-text/8559384/pubmed\" id=\"8559384\" target=\"_blank\">",
"        8559384",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fitton A, and Goa KL, &ldquo;Lamotrigine: An Update of its Pharmacology and Therapeutic Use in Epilepsy,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1995, 50(4):691-713.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/28/6602/abstract-text/8536554/pubmed\" id=\"8536554\" target=\"_blank\">",
"        8536554",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garnett WR and Pellock JM, &ldquo;Focus on Lamotrigine: A New Antiepileptic Drug for Patients With Partial Seizures,&rdquo;",
"      <i>",
"       Hosp Formul",
"      </i>",
"      , 1994, 29:806-12.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gilman JT, &ldquo;Lamotrigine: An Antiepileptic Agent for the Treatment of Partial Seizures,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(2):144-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/28/6602/abstract-text/7756713/pubmed\" id=\"7756713\" target=\"_blank\">",
"        7756713",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goa KL, Ross SR, and Chrisp P, &ldquo;Lamotrigine: A Review of Its Pharmacological Properties and Clinical Efficacy in Epilepsy,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1993, 46(1):152-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/28/6602/abstract-text/7691504/pubmed\" id=\"7691504\" target=\"_blank\">",
"        7691504",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harchelroad F, Lang D, and Valeriano J, &ldquo;Lamotrigine Overdose,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1994, 36:372.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lofton AL and Klein-Schwartz W, &ldquo;Evaluation of Lamotrigine Toxicity Reported to Poison Control Centers,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2004, 38(11):1811-5",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/28/6602/abstract-text/15353576/pubmed\" id=\"15353576\" target=\"_blank\">",
"        15353576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Messenheimer JA, &ldquo;Lamotrigine,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1995, 36(Suppl 2):87-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/28/6602/abstract-text/8784217/pubmed\" id=\"8784217\" target=\"_blank\">",
"        8784217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Messenheimer J, &ldquo;Efficacy and Safety of Lamotrigine in Pediatric Patients,&rdquo;",
"      <i>",
"       J Child Neurol",
"      </i>",
"      , 2002, 17(Suppl 2):34-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/28/6602/abstract-text/11952035/pubmed\" id=\"11952035\" target=\"_blank\">",
"        11952035",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Myllynen PK, Pienimaki PK, and Vahakangas KH, &ldquo;Transplacental Passage of Lamotrigine in a Human Placental Perfusion System",
"      <i>",
"       in vitro",
"      </i>",
"      and in Maternal and Cord Blood",
"      <i>",
"       in vivo",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 2003, 58(10):677-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/28/6602/abstract-text/12610744/pubmed\" id=\"12610744\" target=\"_blank\">",
"        12610744",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ohman I, Vitols S, and Tomson T, &ldquo;Lamotrigine in Pregnancy: Pharmacokinetics During Delivery, in the Neonate, and During Lactation,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2000, 41(6):709-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/28/6602/abstract-text/10840403/pubmed\" id=\"10840403\" target=\"_blank\">",
"        10840403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sabers A, Buchholt JM, Uldall P, et al, &ldquo;Lamotrigine Plasma Levels Reduced by Oral Contraceptives,&rdquo;",
"      <i>",
"       Epilepsy Res",
"      </i>",
"      , 2001, 47(1-2):151-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/28/6602/abstract-text/11673029/pubmed\" id=\"11673029\" target=\"_blank\">",
"        11673029",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schirop TH, Lufft H, Winkler M, et al, &ldquo;Bronchial Mucosa Reaction in Lyell-Stevens-Johnson Syndrome Following Lamotrigine,&rdquo;",
"      <i>",
"       Intensivmedizin und Notfallmedizin",
"      </i>",
"      , 1994, 31:343.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suppes T, Dennehy EB, Hirschfeld RMA, et al, &ldquo;The Texas Implementation of Medication Algorithms: Update to the Algorithms for the Treatment of Bipolar I Disorder,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2005, 66(7):870-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/28/6602/abstract-text/16013903/pubmed\" id=\"16013903\" target=\"_blank\">",
"        16013903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tennis P and Eldridge RR, &ldquo;Preliminary Results on Pregnancy Outcomes in Women Using Lamotrigine. International Lamotrigine Pregnancy Registry Scientific Advisory Committee,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2002, 43(10):1161-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/28/6602/abstract-text/12366730/pubmed\" id=\"12366730\" target=\"_blank\">",
"        12366730",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9545 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-2332FC6495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_28_6602=[""].join("\n");
var outline_f6_28_6602=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709006\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186304\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186305\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186348\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186309\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186329\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186310\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186311\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186312\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186277\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186262\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874647\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186282\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186281\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186355\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186346\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186286\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186266\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299573\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186271\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186300\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186273\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186289\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186316\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3345147\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186288\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186275\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186278\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186291\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186265\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186285\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9545\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9545|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/40/41605?source=related_link\">",
"      Lamotrigine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/34/3626?source=related_link\">",
"      Lamotrigine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_28_6603="Dysphagia grading system";
var content_f6_28_6603=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dysphagia grading system",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Dysphagia",
"      </td>",
"      <td class=\"subtitle1\">",
"       Symptom",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Grade 0",
"      </td>",
"      <td>",
"       Able to swallow all solid foods without difficulty",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Grade 1",
"      </td>",
"      <td>",
"       Able to swallow solid foods with some difficulty",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Grade 2",
"      </td>",
"      <td>",
"       Able to swallow soft or semi solid foods only",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Grade 3",
"      </td>",
"      <td>",
"       Able to swallow liquefied foods and liquids only",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Grade 4",
"      </td>",
"      <td>",
"       Unable to swallow liquids/saliva",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Coia LR, Myerson RJ, Tepper JE. Late effects of radiation therapy on the gastrointestinal tract. Int J Radiat Oncol Biol Phys 1995; 31:1213.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_28_6603=[""].join("\n");
var outline_f6_28_6603=null;
var title_f6_28_6604="Endocrine risk cancer survivors";
var content_f6_28_6604=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Endocrine complications based on specific tumors and their treatment",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Representative tumor, location",
"       </td>",
"       <td class=\"subtitle1\">",
"        Therapy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Highest endocrine risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hodgkin's lymphoma",
"       </td>",
"       <td>",
"        Chemotherapy, mantle irradiation",
"       </td>",
"       <td>",
"        Primary hypothyroidism, primary hypogonadism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhabdomyosarcoma or neuroblastoma, pelvis",
"       </td>",
"       <td>",
"        Excision, chemotherapy, focal radiation",
"       </td>",
"       <td>",
"        Primary gonadal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ALL",
"       </td>",
"       <td>",
"        Chemotherapy and 18 GY cranial radiation",
"       </td>",
"       <td>",
"        Growth hormone deficiency (GHD), early onset puberty, rapid tempo of puberty, osteoporosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AML",
"       </td>",
"       <td>",
"        Chemotherapy to achieve remission, bone marrow transplant (12 GY total body radiation)",
"       </td>",
"       <td>",
"        Primary hypothyroidism, primary hypogonadism, reduced epiphyseal growth (direct effect of radiation), GHD, central hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medulloblastoma, posterior fossa",
"       </td>",
"       <td>",
"        Surgical excision, chemotherapy, craniospinal irradiation, and posterior fossa \"boost\" to 50 Gy",
"       </td>",
"       <td>",
"        Reduced spinal growth, central or primary or mixed hypothyroidism, GHD, precocious puberty and/or gonadotropin deficiency, ACTH deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Craniopharyngioma, suprasellar",
"       </td>",
"       <td>",
"        Biopsy, excision and &nbsp;focal radiation 30 to 50 Gy",
"       </td>",
"       <td>",
"        Panhypopituitarism, diabetes insipidus, precocious puberty or gonadotropin deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhabdomyosarcoma, nasopharyngeal",
"       </td>",
"       <td>",
"        Excision, focal radiation 30 to 50 Gy, and chemotherapy",
"       </td>",
"       <td>",
"        Panhypopituitarism, central or primary or mixed hypothyroidism",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_28_6604=[""].join("\n");
var outline_f6_28_6604=null;
var title_f6_28_6605="Differential dx NLPHL";
var content_f6_28_6605=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F57098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F57098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        NLPHL",
"       </td>",
"       <td class=\"subtitle1\">",
"        LRCHL",
"       </td>",
"       <td class=\"subtitle1\">",
"        T/HRBCL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Clinical presentation",
"       </td>",
"       <td>",
"        53 percent Stage I",
"       </td>",
"       <td>",
"        46 percent Stage I",
"       </td>",
"       <td>",
"        8 percent Stage I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        28 percent Stage II",
"       </td>",
"       <td>",
"        24 percent Stage II",
"       </td>",
"       <td>",
"        8 percent Stage II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14 percent Stage III",
"       </td>",
"       <td>",
"        24 percent Stage III",
"       </td>",
"       <td>",
"        15 percent Stage III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6 percent Stage IV",
"       </td>",
"       <td>",
"        6 percent Stage IV",
"       </td>",
"       <td>",
"        69 percent Stage IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10 percent B symptoms",
"       </td>",
"       <td>",
"        10 percent B symptoms",
"       </td>",
"       <td>",
"        54 percent B symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neoplastic cells",
"       </td>",
"       <td>",
"        L&amp;H cell",
"       </td>",
"       <td>",
"        Reed-Sternberg cell which can resemble L&amp;H cells or lacunar cells",
"       </td>",
"       <td>",
"        Can resemble the L&amp;H cell, centroblast, immunoblast, or Reed-Sternberg cell",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Background cells",
"       </td>",
"       <td>",
"        B cells &gt;T cells small B cells, CD3+CD4+CD57+ T cells and follicular dendritic cells",
"       </td>",
"       <td>",
"        Variable. In nodular cases, Reed-Sternberg cells may be found adjacent to B cell follicles",
"       </td>",
"       <td>",
"        T cells &gt;B cells CD8+ cytotoxic T cells and histiocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Growth pattern",
"       </td>",
"       <td>",
"        Nodular, at least in part",
"       </td>",
"       <td>",
"        Usually nodular but can be diffuse",
"       </td>",
"       <td>",
"        Usually diffuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Tumor cell immunophenotype",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CD15",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CD30",
"       </td>",
"       <td>",
"        -/+",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        -/+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CD20",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -/+",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CD45",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        EMA",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        BOB-1",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -/+",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        OCT-2",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -/+",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        BLC6",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -/+",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NLPHL: Nodular lymphocyte-predominant Hodgkin lymphoma; LRCHL: Lymphocyte-rich classical Hodgkin lymphoma; T/HRBCL: T-cell/histiocyte-rich B-cell lymphoma.",
"     <br>",
"      +: all cases positive.",
"      <br>",
"       +/-: majority of cases positive.",
"       <br>",
"        -/+: minority of cases positive.",
"        <br>",
"         -: all cases negative.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_28_6605=[""].join("\n");
var outline_f6_28_6605=null;
var title_f6_28_6606="Contents: End of life care";
var content_f6_28_6606=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/43/3774\">",
"       Oncology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       End of life care",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			End of life care",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/13/41178\">",
"           Approach to symptom assessment in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/60/38858\">",
"           Assessment and management of depression in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/60/30666\">",
"           Assessment and management of dyspnea in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/37/2650\">",
"           End of life considerations for heart failure patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/1/19477\">",
"           Ethical considerations in effective pain management at the end of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/63/44024\">",
"           Ethical issues near the end of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/12/24778\">",
"           Euthanasia and physician assisted suicide",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/29/31190\">",
"           Grief and bereavement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/16/32008\">",
"           Hospice: Philosophy of care and appropriate utilization in the United States",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/8/14473\">",
"           Legal aspects of end of life care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/52/28490\">",
"           Overview of comprehensive patient assessment in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/7/35962\">",
"           Overview of managing common non-pain symptoms in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/37/12890\">",
"           Pain assessment and management in the last weeks of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/6/29801\">",
"           Palliative care: Benefits, services, and models of care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/23/20855\">",
"           Palliative care: Issues specific to geriatric patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/48/6922\">",
"           Palliative care: Overview of fatigue, weakness, and asthenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/34/13866\">",
"           End of life care: Stopping nutrition and hydration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/25/28058\">",
"           Pediatric palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/4/29769\">",
"           Psychosocial issues at the end of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/15/41208\">",
"           Religion, spirituality, and end of life care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/11/4280\">",
"           Sexuality in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/6/39015\">",
"           Survival estimates in advanced cancer",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-75BCD48EBD-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f6_28_6606=[""].join("\n");
var outline_f6_28_6606=null;
var title_f6_28_6607="Cecal volvulus KUB";
var content_f6_28_6607=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cecal volvulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 283px; height: 374px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain abdominal radiograph of a 74-year-old man with severe abdominal pain and distension demonstrates a large air-filled cecum oriented transversely across the mid- abdomen (arrows) extending into the left upper quadrant. These features are consistent with a cecal volvulus. The subtle mural nodularity seen in the wall of the cecum suggests vascular compromise.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_28_6607=[""].join("\n");
var outline_f6_28_6607=null;
